![]() We note that PRIME is a new initiative undertaken by the EMA to provide better scientific guidance and support accelerated review of investigational therapies that address a high unmet medical need. KITE announced that its immuno-oncology candidate, KTE-C19, has been granted access to the Priority Medicines (PRIME) regulatory initiative in Europe by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) and Committee for Advanced Therapies (CAT) for the treatment of patients with refractory diffuse large B-cell lymphoma (DLBCL). Contact Dividend Channel Meet Our Editorial Staff.Kite Pharma, Inc. Minutes data powered by Ticker Technologies, and Mergent. Video widget and dividend videos powered by Market News Video. By visiting, using or viewing this site, youĪgree to the following Full Disclaimer & Terms of UseĪnd Privacy Policy. Liable for any loss or damage caused by your reliance on information obtained. its subsidiaries, partners, officers, employees, affiliates, or agents be held All viewers agree that under noĬircumstances will BNK Invest, Inc. Transaction, or investment strategy is suitable for any specific person. None of the information contained herein constitutes a recommendation that any particular security, portfolio, or any of its affiliates, subsidiaries or partners. Nothing in Dividend Channel is intended to be investment advice, nor does it represent the opinion of, counselįrom, or recommendations by BNK Invest Inc. KITE | Kite Pharma Inc | Dividend History | Dividend Channel | |Ĭopyright © 2010 - 2023, All Rights Reserved Also see the KITE stock dividend history data table along the right-hand column below.įuture Dividend Aristocrats: Close ContendersĭividendRank'ed Dow Transports ComponentsĬrossing Above Their 200 Day Moving AverageĬrossing Below Their 200 Day Moving Averageĭividend Stocks Crossing Above Their 200 DMAĭividend Stocks Crossing Below Their 200 DMA ![]() ![]() Historical dividends, when charted graphically, can reveal the long-term variability and/or growth within the KITE dividend history record. KITE Stock Dividend HistoryThe KITE dividend history graphic shown above is presented after taking into consideration any known stock split occurrences, in order to present the most directly comparable KITE historical dividend comparison possible. KITE - Key Stats (updated Tuesday, October 3, 10:43 AM) Kite Pharma Inc dividend history is presented both in graphical/chart form, and as a KITE dividend history data table along the right-hand column. ![]() When considering the Kite Pharma Inc stock dividend history, we have taken known splits into account, such that the KITE dividend history is presented on a split-adjusted ("apples to apples") basis. Co.'s primary product candidate, KTE-C19, is a CAR-based therapy that targets the CD19 antigen, a protein expressed on the cell surface of B-cell lymphomas and leukemias. Co.'s therapy involves modifying a patient's T cells outside the patient's body (ex vivo) causing the T cells to express chimeric antigen receptors (CARs) or T cell receptors and then reinfusing the engineered T cells back into the patient. uses its engineered autologous cell therapy for the treatment of cancer. Kite Pharma is a clinical-stage biopharmaceutical company focused on the development and commercialization of cancer immunotherapy products designed to target and kill cancer cells. KITE Dividend History & Description - Kite Pharma Inc ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |